Pfizer, Valneva say EMA validates Lyme vaccine marketing application
PFE•EMA validates Lyme vaccine application
- Pfizer, Valneva Lyme vaccine candidate PF-07307405 marketing application validated by the EMA, triggering the start of the agency’s review.
- Filing backed by Phase 3 VALOR data showing more than 70% efficacy in people aged 5 and older; no safety concerns identified.
